M. De Santis

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

A. Balar, P. Grivas, M. S. van der Heijden, 2024, BMC cancer.

Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

E. Verzoni, S. Van Sanden, Haoyao Ruan, 2024, Advances in therapy.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

A. Poprach, G. De Velasco, L. Albiges, 2024, The New England journal of medicine.

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.

S. Mariathasan, M. Özgüroğlu, J. Arranz, 2023, The Lancet. Oncology.

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

S. Mariathasan, R. Banchereau, D. Vučić, 2024, Cell reports. Medicine.

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.

S. Mariathasan, J. Arranz, M. Mencinger, 2023, The Lancet. Oncology.